Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SOD1 | P00441 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117929 | 0.81 | SYK (0.38) | CYP2D6SOD1 | |
| SCHEMBL7120161 | 0.80 | ADRA1A (0.54) | DRD2ADRA1ADRD3HRH4KCNH2 | |
| SCHEMBL7122983 | 0.79 | AURKA (0.43) | — | |
| SCHEMBL11788598 | 0.72 | KDM4E (0.59) | DRD2ADRA1ADRD3HRH4KCNH2 | |
| SCHEMBL13827761 | 0.69 | TOP2A (0.56) | DRD2ADRA1ADRD3HRH4 | |
| SCHEMBL30223381 | 0.69 | TNF (0.56) | DRD2ADRA1ADRD3HRH4KCNH2 | |
| SCHEMBL6701206 | 0.69 | PRKCH (0.55) | DRD2ADRA1ADRD3HRH4KCNH2 | |
| SCHEMBL12963544 | 0.69 | UTS2R (0.56) | DRD2ADRA1ADRD3HRH4KCNH2 | |
| SCHEMBL11793280 | 0.67 | GAA (0.46) | DRD2ADRA1ADRD3HRH4KCNH2 | |
| SCHEMBL15929394 | 0.67 | LMNA (0.53) | DRD2ADRA1ADRD3HRH4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | DRD2 696/4885ADRA1A 1304/4885DRD3 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.